Author

Katsuma Matsui

Peptidream (Japan)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1 Organism:rat· 1

Frequent Co-Authors

Haruaki KurasakiiD· 1 shared Haruhiko Ogawa· 1 shared Hidetomo Kitamura· 1 shared Hirofumi OhashiiD· 1 shared Junpei Yamamoto· 1 shared Kaho Shionoya· 1 shared Kazutaka Nagatomo· 1 shared Kei Sudo· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

Haruaki KurasakiORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

A macrocyclic peptide-based fusion inhibitor targeting SARS-CoV-2 Spike S2 subunit

Hirofumi Ohashi, Tatsuro Kawamura, Masaki Ohuchi, Haruaki Kurasaki, Naoko Iwata‐Yoshikawa, Yuichiro Hirata, Saya Moriyama, Kaho Shionoya, Kazutaka Nagatomo, Takayuki Nagasawa, Junpei Yamamoto, Kei Sudo, Naoko Nakamura, Katsuma Matsui, Haruhiko Ogawa, , Koichi Watashi

This paper identifies PA-001, a macrocyclic peptide that inhibits SARS-CoV-2 infection by targeting the S2 subunit's FPPR region, showing broad antiviral activity and efficacy in animal models and clinical trials.

bioRxiv · Mar 6, 2026 · PreprintMicrobiology